Drug Trial Radar · NCT05906862
AMT-253 in Patients With Selected Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Nov 6, 2023
Primary completion
Sep 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Multitude Therapeutics (Australia) Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
AMT-253Drug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: Up to 24 months
- Maximum Tolerated Dose (MTD)Time frame: Up to 24 months
- Type, incidence and severity of Adverse EventsTime frame: Up to 24 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Blacktown
Sydney, New South Wales, Australia · Recruiting
Chris O'Brien Lifehouse
Sydney, New South Wales, Australia · Recruiting
Maquarie University Hospital
Sydney, New South Wales, Australia · Recruiting
ICON Cancer Centre
Brisbane, Queensland, Australia · Recruiting
Southern Oncology Clinical Research
Adelaide, South Australia, Australia · Recruiting
Cabrini Malvern Hospital
Malvern, Victoria, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.